|
1
|
Menon KV, Hakeem AR and Heaton ND: Review
article: Liver transplantation for hepatocellular carcinoma-a
critical appraisal of the current worldwide listing criteria.
Aliment Pharmacol Ther. 40:893–902. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shariff MI, Cox IJ, Gomaa AI, Khan SA,
Gedroyc W and Taylor-Robinson SD: Hepatocellular carcinoma: Current
trends in worldwide epidemiology, risk factors, diagnosis and
therapeutics. Expert Rev Gastroenterol Hepatol. 3:353–367. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fung SK and Lok AS: Management of patients
with hepatitis B virus-induced cirrhosis. J Hepatol. 42
Suppl:S54–S64. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chinnaratha MA, Chuang MY, Fraser RJ,
Woodman RJ and Wigg AJ: Percutaneous thermal ablation for primary
hepatocellular carcinoma: A systematic review and meta-analysis. J
Gastroenterol Hepatol. 31:294–301. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang YH, Wu JC, Chen SC, Chen CH, Chiang
JH, Huo TI, Lee PC, Chang FY and Lee SD: Survival benefit of
transcatheter arterial chemoembolization in patients with
hepatocellular carcinoma larger than 10 cm in diameter. Aliment
Pharmacol Ther. 23:129–135. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim SS, Cho HJ, Lee HY, Park JH, Noh CK,
Shin SJ, Lee KM, Yoo BM, Lee KJ, Cho SW and Cheong JY: Genetic
polymorphisms in the Wnt/β-catenin pathway genes as predictors of
tumor development and survival in patients with hepatitis B
virus-associated hepatocellular carcinoma. Clin Biochem.
49:792–801. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dhir M, Melin AA, Douaiher J, Lin C, Zhen
WK, Hussain SM, Geschwind JF, Doyle MB, Abou-Alfa GK and Are C: A
review and update of treatment options and controversies in the
management of hepatocellular carcinoma. Ann Surg. 263:1112–1125.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Simonetti RG, Cammà C, Fiorello F, Politi
F, D'Amico G and Pagliaro L: Hepatocellular carcinoma. A worldwide
problem and the major risk factors. Dig Dis Sci. 36:962–972. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zidan A, Scheuerlein H, Schüle S,
Settmacher U and Rauchfuss F: Epidemiological pattern of hepatitis
B and hepatitis C as etiological agents for hepatocellular
carcinoma in iran and worldwide. Hepat Mon. 12:e68942012.PubMed/NCBI
|
|
10
|
Guo Z, Yu H, Liu C, Si T, Yang X, Zhang W,
Xu Y and Li Y: Advances in endovascular therapy to treat primary
hepatocellular carcinoma. Drug Discov Ther. 9:342–351. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang J, Yu C, Chen M, Tian S and Sun C:
Over-expression of TRIM37 promotes cell migration and metastasis in
hepatocellular carcinoma by activating Wnt/beta-catenin signaling.
Biochem Biophys Res Commun. 464:1120–1127. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Forner A, Reig M, Varela M, Burrel M,
Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao
JI, et al: Diagnosis and treatment of hepatocellular carcinoma.
Update consensus document from the AEEH, SEOM, SERAM, SERVEI and
SETH. Med Clin (Barc). 146:511.e1–511.e22. 2016.(In Spanish).
View Article : Google Scholar
|
|
13
|
Kim JH, Badawi M, Park JK, Jiang J, Mo X,
Roberts LR and Schmittgen TD: Anti-invasion and anti-migration
effects of miR-199a-3p in hepatocellular carcinoma are due in part
to targeting CD151. Int J Oncol. 49:2037–2045. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu M, Liu Q, Jia Y, Tu K, Yao Y and Guo C:
BCAT1 promotes tumor cell migration and invasion in hepatocellular
carcinoma. Oncol Lett. 12:2648–2656. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheng XS, Sun SB, Zhong F, He K and Zhou
J: Knockdown of histone methyltransferase hSETD1A inhibits
progression, migration, and invasion in human hepatocellular
carcinoma. Oncol Res. 24:239–245. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu L, Zhang M, Zheng X, Yi P, Lan C and Xu
M: The circular RNA ciRS-7 (Cdr1as) acts as a risk factor of
hepatic microvascular invasion in hepatocellular carcinoma. J
Cancer Res Clin Oncol. 143:17–27. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen YJ, Chen CC and Huang HL: Induction
of apoptosis by Armillaria mellea constituent armillarikin in human
hepatocellular carcinoma. Onco Targets Ther. 9:4773–4783. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Banjerdpongchai R, Wudtiwai B and Khawon
P: Induction of human hepatocellular carcinoma HepG2 cell apoptosis
by naringin. Asian Pac J Cancer Prev. 17:3289–3294. 2016.PubMed/NCBI
|
|
19
|
Wang K, Ren Y, Liu Y, Zhang J and He JJ:
Tumor necrosis factor (TNF)-α-induced protein 8-like-2 (TIPE2)
inhibits proliferation and tumorigenesis in breast cancer cells.
Oncol Res. 25:55–63. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cao X, Zhang L, Shi Y, Sun Y, Dai S, Guo
C, Zhu F, Wang Q, Wang J, Wang X, et al: Human tumor necrosis
factor (TNF)-alpha-induced protein 8-like 2 suppresses
hepatocellular carcinoma metastasis through inhibiting Rac1. Mol
Cancer. 12:1492013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li XM, Su JR, Yan SP, Cheng ZL, Yang TT
and Zhu Q: A novel inflammatory regulator TIPE2 inhibits
TLR4-mediated development of colon cancer via caspase-8. Cancer
Biomark. 14:233–240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao Q, Zhao M, Dong T, Zhou C, Peng Y,
Zhou X, Fan B, Ma W, Han M and Liu S: Tumor necrosis
factor-α-induced protein-8 like-2 (TIPE2) upregulates p27 to
decrease gastic cancer cell proliferation. J Cell Biochem.
116:1121–1129. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ruan Q, Wang P, Wang T, Qi J, Wei M, Wang
S, Fan T, Johnson D, Wan X, Shi W, et al: MicroRNA-21 regulates
T-cell apoptosis by directly targeting the tumor suppressor gene
Tipe2. Cell Death Dis. 5:e10952014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Renshaw A and Elsheikh TM: A validation
study of the Focalpoint GS imaging system for gynecologic cytology
screening. Cancer Cytopathol. 121:737–738. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Poon RT, Fan ST, O'Suilleabhain CB and
Wong J: Aggressive management of patients with extrahepatic and
intrahepatic recurrences of hepatocellular carcinoma by combined
resection and locoregional therapy. J Am Coll Surg. 195:311–318.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Au WY, Lie AK, Liang R, Liu CL, Shek TW
and Lau GK: Aggressive hepatocellular carcinoma complicating
pregnancy after autologous bone marrow transplantation for
non-Hodgkin's lymphoma. Bone Marrow Transplant. 29:177–179. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lubienski A, Bitsch RG, Schemmer P,
Grenacher L, Dux M and Kauffmann GW: Long-term results of
interventional treatment of large unresectable hepatocellular
carcinoma (HCC): Significant survival benefit from combined
transcatheter arterial chemoembolization (TACE) and percutaneous
ethanol injection (PEI) compared to TACE monotherapy. Rofo.
176:1794–1802. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yeh ML, Huang CI, Huang CF, Hsieh MY,
Huang JF, Dai CY, Lin ZY, Chen SC, Yu ML and Chuang WL: Neoadjuvant
transcatheter arterial chemoembolization does not provide survival
benefit compared to curative therapy alone in single hepatocellular
carcinoma. Kaohsiung J Med Sci. 31:77–82. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu QQ, Zhang FF, Wang F, Qiu JH, Luo CH,
Zhu GY and Liu YF: TIPE2 inhibits lung cancer growth attributing to
promotion of apoptosis by regulating some apoptotic molecules
expression. PLoS One. 10:e01261762015. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
López-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum
Pathol. 40:1512–1515. 2009. View Article : Google Scholar
|
|
32
|
Huang CS, Lee YR, Chen CS, Tu SH, Wang YJ,
Lee CH, Chen LC, Chang HW, Chang CH, Chih-Ming S, et al: Long-term
ethanol exposure causes human liver cancer cells to become
resistant to mitomycin C treatment through the inactivation of
bad-mediated apoptosis. Mol Carcinog. 49:728–738. 2010.PubMed/NCBI
|
|
33
|
Zhang YH, Yan HQ, Wang F, Wang YY, Jiang
YN, Wang YN and Gao FG: TIPE2 inhibits TNF-α-induced hepatocellular
carcinoma cell metastasis via Erk1/2 downregulation and NF-κB
activation. Int J Oncol. 46:254–264. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Handayani T, Sakinah S, Nallappan M and
Pihie AH: Regulation of p53-, Bcl-2- and caspase-dependent
signaling pathway in xanthorrhizol-induced apoptosis of HepG2
hepatoma cells. Anticancer Res. 27:965–971. 2007.PubMed/NCBI
|
|
35
|
Zhang LJ, Li ZQ, Yang YP, Li XW and Ji JF:
Tunicamycin suppresses cisplatin-induced HepG2 cell apoptosis via
enhancing p53 protein nuclear export. Mol Cell Biochem.
327:171–182. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Baiz D, Pozzato G, Dapas B, Farra R,
Scaggiante B, Grassi M, Uxa L, Giansante C, Zennaro C, Guarnieri G
and Grassi G: Bortezomib arrests the proliferation of
hepatocellular carcinoma cells HepG2 and JHH6 by differentially
affecting E2F1, p21 and p27 levels. Biochimie. 91:373–382. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lin YW and Chiang BH:
4-acetylantroquinonol B isolated from Antrodia cinnamomea arrests
proliferation of human hepatocellular carcinoma HepG2 cell by
affecting p53, p21 and p27 levels. J Agric Food Chem. 59:8625–8631.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shin DY, Kim GY, Hwang HJ, Kim WJ and Choi
YH: Diallyl trisulfide-induced apoptosis of bladder cancer cells is
caspase-dependent and regulated by PI3K/Akt and JNK pathways.
Environ Toxicol Pharmacol. 37:74–83. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hatashita M, Taniguchi M, Baba K, Koshiba
K, Sato T, Jujo Y, Suzuki R and Hayashi S: Sinodielide A exerts
thermosensitizing effects and induces apoptosis and G2/M cell cycle
arrest in DU145 human prostate cancer cells via the Ras/Raf/MAPK
and PI3K/Akt signaling pathways. Int J Mol Med. 33:406–414. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yue S, Li J, Lee SY, Lee HJ, Shao T, Song
B, Cheng L, Masterson TA, Liu X, Ratliff TL and Cheng JX:
Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT
activation underlies human prostate cancer aggressiveness. Cell
Metab. 19:393–406. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
de SàBacelar T, da Silva AJ, Costa PR and
Rumjanek VM: The pterocarpanquinone LQB 118 induces apoptosis in
tumor cells through the intrinsic pathway and the endoplasmic
reticulum stress pathway. Anticancer Drugs. 24:73–83. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Edagawa M, Kawauchi J, Hirata M, Goshima
H, Inoue M, Okamoto T, Murakami A, Maehara Y and Kitajima S: Role
of activating transcription factor 3 (ATF3) in endoplasmic
reticulum (ER) stress-induced sensitization of p53-deficient human
colon cancer cells to tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL)-mediated apoptosis through
up-regulation of death receptor 5 (DR5) by zerumbone and celecoxib.
J Biol Chem. 289:21544–21561. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lu Q, Liu Z, Li Z, Chen J, Liao Z, Wu WR
and Li YW: TIPE2 overexpression suppresses the proliferation,
migration and invasion in prostate cancer cells by inhibiting
PI3K/Akt signaling pathway. Oncol Res. 24:305–313. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li Z, Guo C, Liu X, Zhou C, Zhu F, Wang X,
Wang Q, Shi Y, Wang J, Zhao W and Zhang L: TIPE2 suppresses
angiogenesis and non-small cell lung cancer (NSCLC) invasiveness
via inhibiting Rac1 activation and VEGF expression. Oncotarget.
7:62224–62239. 2016.PubMed/NCBI
|
|
45
|
Tang J, Guo YS, Zhang Y, Yu XL, Li L,
Huang W, Li Y, Chen B, Jiang JL and Chen ZN: CD147 induces UPR to
inhibit apoptosis and chemosensitivity by increasing the
transcription of Bip in hepatocellular carcinoma. Cell Death
Differ. 19:1779–1790. 2012. View Article : Google Scholar : PubMed/NCBI
|
